UBS Group AG Acquires 395,622 Shares of Oric Pharmaceuticals, Inc. $ORIC

UBS Group AG increased its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 116.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 734,858 shares of the company’s stock after buying an additional 395,622 shares during the period. UBS Group AG’s holdings in Oric Pharmaceuticals were worth $6,011,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assetmark Inc. bought a new stake in shares of Oric Pharmaceuticals during the 3rd quarter worth approximately $37,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Oric Pharmaceuticals by 36.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,755 shares of the company’s stock worth $45,000 after purchasing an additional 1,009 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Oric Pharmaceuticals during the 3rd quarter worth approximately $60,000. CANADA LIFE ASSURANCE Co acquired a new stake in Oric Pharmaceuticals in the third quarter valued at $65,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Oric Pharmaceuticals in the third quarter valued at about $120,000. Institutional investors own 95.05% of the company’s stock.

Insider Buying and Selling

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 52,000 shares of the company’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. This represents a 43.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.70% of the stock is currently owned by insiders.

Oric Pharmaceuticals Price Performance

NASDAQ:ORIC opened at $8.41 on Thursday. The stock’s fifty day moving average price is $10.20 and its two-hundred day moving average price is $10.65. The company has a market cap of $870.60 million, a P/E ratio of -5.84 and a beta of 1.11. Oric Pharmaceuticals, Inc. has a 1 year low of $5.51 and a 1 year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, analysts expect that Oric Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

ORIC has been the subject of a number of analyst reports. Citigroup lowered their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wedbush reduced their price target on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, April 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Friday, May 15th. Finally, Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of Oric Pharmaceuticals in a research note on Tuesday, February 24th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oric Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $19.36.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.